ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034

 

Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

 

Close Window

ProteoTech

A World Leader in Therapeutics and

Diagnostics Targeting Amyloid Diseases

ProteoTech

 

 

March 09, 2009

ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009

 

February 26, 2009

ProteoTech Receives Funding from The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain

 

December, 2008

"Advances In: Treating Alzheimer's" - ProteoTech's Alzheimer's Drug Exebryl-1® was featured in the Dec 2008 Issue of Reader's Digest

 

November 11, 2008

ProteoTech to Present at Rodman & Renshaw's 10th Annual Healthcare Conference

 

August 07, 2008

ProteoTech's Exebryl-1® Enters Human Clinical Trials for the Treatment of Alzheimer's Disease

 

February, 2006

Michael J. Fox Foundation to Provide Up to $3.1 Million for Development of New Therapy to Stop Parkinson's Progression

 

August 4, 2004

ProteoTech Receives Phase I SBIR Award from the National Institute on Aging to Study the Role of Proteoglycans in Brain During Development of Alzheimer's Disease

 

September 24, 2004

ProteoTech Receives Phase I SBIR Award From the National Institute of Health to Develop Small Molecule Therapeutics for the Treatment of Systemic AA Amyloidosis

 

May 27, 2003

ProteoTech Receives Issuance of US Patent Pertaining to the Generation of Proteoglycan Transgenic Mice

 

June 5, 2003

ProteoTech Receives Phase I SBIR Award from the National Institute on Aging to Study the Role of Proteoglycans in Brain During Development of Alzheimer's Disease

 

October 2, 2002

ProteoTech Receives Issuance of US Patent Pertaining to Diagnostic Applications of Particular Proteoglycans

 

January 21, 1994 Wall Street Journal

Study With Rats Mimics Damage From Alzheimer's

News

April, 2009 ProteoTech presents at the 11th annual C21 BioVentures Conference in Napa, California

April, 2009 ProteoTech meets all scientific milestones for the Michael J. Fox foundation LEAPS award to continue development of Synuclere for treatment of Parkinson's disease.

March 09, 2009 ProteoTech presents at 9th International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009

February 26, 2009 ProteoTech receives funding from The Michael J. Fox Foundation for Parkinson's Disease research to develop tools for imaging Alpha-Synuclein aggregation in living Parkinson's Brain

December, 2008 ProteoTech's Alzheimer's Drug Exebryl-1® was featured in the Dec 2008 Issue of Reader's Digest

November 11, 2008 ProteoTech presents at Rodman & Renshaw's 10th Annual Healthcare Conference

August 07, 2008 ProteoTech's Exebryl-1® enters human clinical trials for the treatment of Alzheimer's Disease

July 29, 2008 Exebryl-1® Phase I human clinical trial for Alzheimer's disease commences

July 25, 2008 ProteoTech presents at International Alzheimer's Conference—Chicago, IL.

May 28, 2008 ProteoTech receives clearance from FDA to proceed with Phase I human clinical trials for Exebryl-1®

May 15, 2008 ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

April 28, 2008 ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease

 

ProteoTech